New PANCAID review hot off the digital press! Kim-Lea Reese, Prof. Klaus Pantel, and Dr. Dr. Daniel J. Smit from Universitätsklinikum Hamburg Eppendorf just published a narrative review, where they present an overview of different #liquidbiopsy biomarkers for the early diagnosis of Pancreatic ductal adenocarcinoma (PDAC) and discuss the validity of multimarker panels. Read the full article here (it’s #OpenAccess) 🔓 https://lnkd.in/dPdWy2ns This review is part of PANCAID’s #workpackage 2! #PancreaticCancer #cancerresearch #oncology
PANCAID’s Post
More Relevant Posts
-
This is the communication office of Pancreatic Cancer Europe (PCE). Connect with us to keep updated on events and conferences, as well as to network with experts, organisations and patients
Check out the comprehensive review published by the partners of WP2 of the PANCAID project, which PCE is a part of! 👇
New PANCAID review hot off the digital press! Kim-Lea Reese, Prof. Klaus Pantel, and Dr. Dr. Daniel J. Smit from Universitätsklinikum Hamburg Eppendorf just published a narrative review, where they present an overview of different #liquidbiopsy biomarkers for the early diagnosis of Pancreatic ductal adenocarcinoma (PDAC) and discuss the validity of multimarker panels. Read the full article here (it’s #OpenAccess) 🔓 https://lnkd.in/dPdWy2ns This review is part of PANCAID’s #workpackage 2! #PancreaticCancer #cancerresearch #oncology
-
Review ESMO abstracts in minutes. 🔍 We build a tool to extract primary target + other genes (e.g. biomarkers) from ESMO poster abstracts. This is work-in-progress, but try it out now: https://lnkd.in/eQSz323a Curious to learn more? Let us know about your use cases and we'd be happy to explore together! #ESMO24 #ESMO2024 #Oncology #CancerResearch
-
-
Dr. Ann-Lii Cheng, the 2020 Blue Faery Award recipient, has worked in the development of sorafenib and lenvatinib, two pivotal drugs in the first-line treatment of HCC and recently the discovery of a new regimen, atezolizumab plus bevacizumab, which is considered an epoch-making breakthrough in this field. His research team at National Taiwan University has been recognized as one of the most prominent translational research groups in exploring the frontier of HCC treatment. If you research primary liver cancer, you can apply for the Blue Faery Award here: https://vist.ly/xdue #livercancer #liverdisease #researchstudy #bluefaeryaward
-
-
ICYMI: This course presented at the 2023 ARRS Annual Meeting offers a collection of focused talks detailing approaches to pancreatic cancer staging, pancreatic cysts, and dual energy applications. https://lnkd.in/ejf7KskP
-
-
NEW PUBLICATION: Primary analysis of the Phase III INAVO120 study investigating the 1L use of a novel PI3Ki with a CDK4/6i and an estrogen receptor antagonist in adult patients with endocrine resistant, PIK3CAm, HR+, HER2- locally advanced/metastatic #BreastCancer. #Oncology https://lnkd.in/gnMNrN3Y
-
"The state of the art of EGFR exon 20 insertions in non-small cell #lungcancer: Diagnosis and future perspectives". It's a paper written -among other doctors - by Dr. Delvys Rodriguez-Abreu, MD, PhD. By clicking on this link you will be taken directly to the article. You are welcome to access and share this work easily through this link. We support #research, we encourage you to share it! ➡ https://lnkd.in/d58rzNVU #oncology #lungcancer #FCCP
-
-
Dear network, are you heading to #AACR in #SanDiego next week? Please join my colleagues Ankush Madaan PhD, B.Pharm Marijana Rucevic and Antoine Italiano from #GustaveRoussy for an exciting seminar on how Olink Proteomics #PEA #technology can aid early cancer detection with minimal #biosample input. #cancerproteomics #earlydetection #aacr24 #oncology
Interested in learning more about how proteomic plasma biomarkers are used for target identification, treatment assessment, and deciphering patterns of sensitivity and resistance in cancer patients? Join Italiano Antoine, MD, PhD and Marijana Rucevic, PhD on Tuesday, April 9, from 3:00 p.m. - 4:00 p.m. PST in Theater A at AACR. Learn more here: https://bit.ly/4aq9BaV #AACR24 #oncology #biomarkers #clinicaltrials
-
-
This week is #BrainTumourAwarenessWeek which we at #Ariceum fully support, with a focus on recurrent #glioblastoma, an aggressive form of brain #cancer with a high unmet medical need. Ariceum is striving to develop a much-needed therapy for this devastating form of #braincancer, having commenced our Phase 1 first-in-human trial (CITADEL-123) of ¹²³I-ATT001, Ariceum's Iodine-123 labelled PARP inhibitor, in patients with recurrent glioblastoma. Find out more information about Ariceum's CITADEL-123 Phase 1 trial conducted at University College London Hospitals NHS Foundation Trust (#UCLH) on our website linked in the comments below 👇 #biotech #oncology #lifesciences #ATT001 #BrainTumourAwareness
-
-
🌟 𝗡𝗲𝘄 𝗘𝗽𝗶𝘀𝗼𝗱𝗲 𝗔𝗹𝗲𝗿𝘁: "𝗪𝗵𝗮𝘁’𝘀 𝗡𝗲𝘄 𝗗𝗼𝗰? 𝗶𝗻 𝗟𝘂𝗻𝗴 𝗖𝗮𝗻𝗰𝗲𝗿" 🌟 The MARIPOSA-2 Trial: A Beacon of Hope for NSCLC Patients, Explored by Prof Mariana Brandao and Prof Johan Vansteenkiste. 👇 Watch all WND Lung videos - link in the comments! #MediMix #LungCancer #Immunotherapy #Oncology
-
Our EPICS Global Perspectives in #BreastCancer report will provide worldwide reactions to new data from #ESMO24. To get the report and observe the discussion: https://lnkd.in/eUnmaV9q Topics include approaches in triple negative; new standards in HR+, HER2–; and HER2+. #CancerCare #Oncology #ESMO2024
-
